Tags

Type your tag names separated by a space and hit enter

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.
J Infect. 2020 08; 81(2):318-356.JI

Authors+Show Affiliations

Rheumatology Department, Azienda USL Toscana Centro, Hospital of Prato, Piazza Ospedale 1. Electronic address: fbrzcantini@gmail.com.Rheumatology Department, Azienda USL Toscana Centro, Hospital of Prato, Piazza Ospedale 1.Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: daniela.matarrese@uslcentro.toscana.it.National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Via Portuense, 292, Rome 00149, Italy. Electronic address: emanuele.nicastri@inmi.it.AOS Antonio e Biagio e C. Arrigo, Rheumatology Unit - Alessandria, Italy. Electronic address: pstobbione@ospedale.al.it.National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Via Portuense, 292, Rome 00149, Italy; Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Via Portuense 292, 00149 Rome, Italy. Electronic address: delia.goletti@inmi.it.

Pub Type(s)

Letter
Comment

Language

eng

PubMed ID

32333918

Citation

Cantini, Fabrizio, et al. "Baricitinib Therapy in COVID-19: a Pilot Study On Safety and Clinical Impact." The Journal of Infection, vol. 81, no. 2, 2020, pp. 318-356.
Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2):318-356.
Cantini, F., Niccoli, L., Matarrese, D., Nicastri, E., Stobbione, P., & Goletti, D. (2020). Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. The Journal of Infection, 81(2), 318-356. https://doi.org/10.1016/j.jinf.2020.04.017
Cantini F, et al. Baricitinib Therapy in COVID-19: a Pilot Study On Safety and Clinical Impact. J Infect. 2020;81(2):318-356. PubMed PMID: 32333918.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. AU - Cantini,Fabrizio, AU - Niccoli,Laura, AU - Matarrese,Daniela, AU - Nicastri,Emanuele, AU - Stobbione,Paolo, AU - Goletti,Delia, Y1 - 2020/04/23/ PY - 2020/04/11/received PY - 2020/04/13/revised PY - 2020/04/16/accepted PY - 2020/4/26/pubmed PY - 2020/8/4/medline PY - 2020/4/26/entrez SP - 318 EP - 356 JF - The Journal of infection JO - J Infect VL - 81 IS - 2 SN - 1532-2742 UR - https://www.unboundmedicine.com/medline/citation/32333918/Baricitinib_therapy_in_COVID_19:_A_pilot_study_on_safety_and_clinical_impact_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-4453(20)30228-0 DB - PRIME DP - Unbound Medicine ER -